Observe Medical ASA · OSL:OBSRV

Observe Medical ASA — Investor Presentation (April 2025)

23 slides from Observe Medical ASA's investor presentation, Apr 10, 2025

  1. Slide 1: Investor Presentation // trading update

    Investor Presentation // trading update 10 April 2025

  2. Slide 2: Copyright and disclaimer

    Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Observe Medical and third-party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any fo

  3. Slide 3: Strategic Vision

    STRATEGIC VISION

  4. Slide 4: Strategic Vision: Nordic Medtech Platform

    Strategic Vision: Nordic Medtech Platform Scalable and profitable growth, product development, regulatory performance and effective manufacturing Proprietary Platform for innovative “M&A products Nordic ecosystem Opportunities” Start-ups with limited access to Commercialisation and portfolio commerc

  5. Slide 5: Commercial Strategy – Progress and Plans

    COMMERCIAL STRATEGY – PROGRESS AND PLANS

  6. Slide 6: Truly transformative years

    Truly transformative years 2025 2023 2020-2021 Market Penetration with complete Regulatory integration and Convatec portfolio Focus on launching Commercial launch of UnoMeter • First UnoMeterTM SafetiTM Plus Sippi® in selected 500 and Abdo-Pressure products arriving in January – markets invoicing ac

  7. Slide 7: Observe Medical: Nordic medtech company with global reach

    Observe Medical Nordic medtech company with global reach Strong Medtech Portfolio Pocketable Distribution and M&A Urine Output Measurement Ultrasound Opportunities Scalable Platform Manufacturing Product Development Sales & Distribution Quality & Regulatory 7

  8. Slide 8: Market potential – Urine Output measurement systems

    Market potential – Urine Output measurement systems Sippi® Current market value for manual systems NOK 1.5 bn ✓ Current global market potential 679 1.548 Market potential OM design 870 Market potential US Design ✓ Sales generated through sales of Based unit and disposable system ✓ Sippi® will give a

  9. Slide 9: Product launch planning 2024-2025 - taking the position as global leader in Urine Output Measurement

    Product launch planning 2024-2025 - taking the position as global leader in Urine Output Measurement Upsell Sippi and Safeti Max to existing Expand portfolio to Recapture the market through UnoMeter family of products clients at higher price points and better allow access to full margins market pote

  10. Slide 10: Product portfolio completed and approved for marketing

    Product portfolio completed and approved for marketing Execute on recapturing UnoMeter ’s historical market 2021 annual recurring revenue 2021 annual recurring revenue UnoMeterTM 500 and UnoMeterTM Abdo- UnoMeterTM 500, UnoMeter Safeti Plus and UnoMeterTM PressureTM Abdo-PressureTM Total value: NOK

  11. Slide 11: Marketing collateral completed

    Marketing collateral completed Clinical documentation CE-Certificate (MDR), Marketing Collateral Data Sheets & support materials DoC etc. 11

  12. Slide 12: Order intake – two months after delivery of first samples of UnoMeter Safeti Plus

    Order intake – two months after delivery of first samples of UnoMeter Safeti Plus Spain Germany 10,3 Latest development Italy UK • First ever order from France Nordics • First ever order from Chile Switzerland • First Safeti Plus order from Ireland Holland/Belgium/Luxembourg Austria Poland Spain Cro

  13. Slide 13: Continued market confirmation after launch of UnoMeter Safeti Plus

    Continued market confirmation after launch of UnoMeter Safeti Plus Sales process: 24 • Most common first step is for distributors to place sample orders • The sample orders are used to confirm product quality and drive end-user Repeat orders 42% conversion and tender wins 10 58% 1st order • Successf

  14. Slide 14: 83% Geographical coverage and next steps

    83% Geographical coverage and next steps • Finalize ongoing market evaluations and tender Orders received from the following countries indicating processes: their share of 2021 Convatec net sales Chile: Austria: Holland: Ireland: • UK Belgium: Poland: UAE: • Germany Switzerland: Thailand: 3% 3% 2% 2

  15. Slide 15: The clinical challenge in intensive care..

    The clinical challenge in intensive care.. 1. Catheter-Associated Urinary Tract Infection (CAUTI) 2. Nursing safety and time optimization 3. Maki DG, Tambyah PA; Engineering out the risk of Infection with Urinary Catheters. Emerging Infectious Diseases: Vol. 7, no. 2, March-April 2001. 4. Marra, A.

  16. Slide 16: Preparations for launch of UnoMeter Safeti MAX

    Preparations for launch of UnoMeter Safeti MAX • We have patented technology from Sippi that we expect to be able to provide increased protection towards CAUTI – catheter associated urinary infection. • We can start the production of UnoMeter tomorrow – first 100 sterile units being prepared for pil

  17. Slide 17: Sippi® eliminates one of the last manual monitoring procedures in the ICU

    Sippi® eliminates one of the last manual monitoring procedures in the ICU Addressing key burdens of current clinical practice, A unique, automated, digital urine meter with wireless representing considerable added value and cost savings data transfer and biofilm control Burdens of current Patient we

  18. Slide 18: Biim

    Biim Fresenius Medical Care finalized pilot study in Q4 intended to identify value drivers and drive a decision towards scaling of ultrasound intro remaining 2500 clinics During a recent pilot study which was completed in December a number of positive indicators have been identified. Based on that a

  19. Slide 19: Financials

    FINANCIALS Keone

  20. Slide 20: Ramp-up from a diversified revenue stream

    Ramp-up from a diversified revenue stream Strong revenue outlook in the medium term ✓ Diversified revenue stream going forward from UnoMeter product family, Sippi® and ambition within the distribution business ~400-450m ✓ Gross margin currently under pressure on commoditized products, differentiated

  21. Slide 21: Summary

    SUMMARY Keone

  22. Slide 22: Summary

    Summary Products launched Ongoing market penetration Strong pipeline 22

  23. Slide 23: Slide 23

Observe Medical — Investor Presentation (April 2025) on 6ix